<DOC>
	<DOCNO>NCT00613327</DOCNO>
	<brief_summary>The objective study evaluate efficacy oxybutynin chloride oral osmotic therapeutic system ( OROS ) patient-reported outcomes 12 week treatment dose escalation participant overactive bladder .</brief_summary>
	<brief_title>An Efficacy Safety Study Oxybutynin Chloride Oral Osmotic Therapeutic System ( OROS ) Korean Overactive Bladder Participants</brief_title>
	<detailed_description>This multicenter ( one hospital medical school team work medical research study ) , open-label ( people know identity intervention ) , prospective ( study follow participant forward time ) Phase 4 study oxybutynin chloride OROS participant overactive bladder . The total study duration 12 week include follow visit : Screening ( Week -2 ) , Baseline , Week 2 , 4 , 6 12 . Participants receive oxybutynin chloride OROS tablet start dose 10 milligram ( mg ) orally daily . The dose adjust 10 mg every 2 week first 6 week , base criterion evaluation optimal dose . The optimal dose obtain first 6 week continue Week 12 . Maximum allow dose 30 mg per day . Efficacy primarily evaluate assessment goal achievement ( percentage participant show score 4 5 Likert scale treatment goal ) Week 12 . Participants ' safety also monitor visit .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>Participants fulfil follow criterion micturition chart complete 3 day prior visit 2 ( Baseline ) : mean voiding frequency great equal 8 time per 24 hour mean frequency urinary urgency great equal 2 time per 24 hour ( urgency mean sudden strong urge urinate urinary sensation scale score great equal 3 micturition chart ) Participants overactive bladder symptom last 3 month longer prior study initiation Participants capable complete micturition chart survey questionnaires provide informed consent complete Participants could sign informed consent form fully listen understand characteristic , risk benefit study Participants stress urinary incontinence ( able control bladder action ) participant complicate incontinence dominantly present stress urinary incontinence judging base medical history Participants hepatic ( pertain liver ) renal ( pertain kidney ) disease indicate serum aspartate transaminase ( AST [ SGOT ] ) , alanine transaminase ( ALT [ SGPT ] ) , alkaline phosphatase creatinnine concentration twice normal upper limit Participants contraindicate use anticholinergic include uncontrolled narrow angle glaucoma ( increased pressure inside eye cause visual problem ) , urinary retention gastrointestinal tract retention Participants experience symptom acute urinary tract infection ( UTI ) runin period Participants recurrent UTI medical history treatment UTI symptom 5 time past one year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Overactive bladder</keyword>
	<keyword>Oxybutynin chloride</keyword>
	<keyword>OROS</keyword>
</DOC>